Beam Therapeutics

8 active clinical studies registered on ClinicalTrials.gov, the most advanced in Phase 1/2. Next estimated primary completion: Dec 2026.

Clinical pipeline

Primary completion	Phase	Status	Condition and study
29 Jan 2026 passed	Phase 1?	Recruiting	Healthy Subjects, Healthy Participant Study This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of BEAM-103 in Healthy Subjects · NCT07304791
Dec 2026	N/A	Recruiting	Sickle Cell Trait Achieving Understanding of the Natural History of Sickle Cell Trait (AUNT) · NCT06071377
Dec 2026	Phase 1/2?	Active, not recruiting	Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Leukemia A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL) · NCT05885464
30 Dec 2027	Phase 1/2?	Recruiting	Glycogen Storage Disease Type Ia A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa) · NCT06735755
Feb 2028	Phase 1/2?	Active, not recruiting	Sickle Cell Disease BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease · NCT05456880
May 2028	Phase 1/2?	Recruiting	Alpha 1-Antitrypsin Deficiency A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD) · NCT06389877
30 May 2029	Phase 1?	Recruiting	T-Cell Acute Lymphoblastic Leukemia/Lymphoma Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma · NCT06934382
12 Feb 2043	N/A	Recruiting	Hemoglobinopathy, Sickle Cell Disease A Long-term Follow-up Study in Patients Who Received BEAM-101 · NCT07373639

Source: ClinicalTrials.gov, studies with the company as sponsor and an active status. Data fetched 7 October 2026.

Beam Therapeutics

Clinical pipeline

Recent news